Abstract :
Helicobacter pylori (H. pylori) is one of the most common infections worldwide, affecting over 50% of the global population. Since its discovery, multiple regimens have been used to treat H. pylori, involving various combinations of antimicrobial agents and differing treatment durations. Despite these efforts, no single regimen has achieved a 100% eradication rate. This study aims to evaluate the pattern of diagnosis, prevalence, and management of the helicobacter pylori infection. A retrospective, cross-sectional study was conducted on 610 randomly selected patients from a total of 5166 individuals who were screened or treated for H. pylori between 2017 and 2020. Data on demographics, diagnostic methods, treatment regimens, and outcomes were collected and analyzed. Among the 610 patients, 47.58% tested positive for H. pylori, while 52.15% were negative. Of the total sample, 44.26% received antimicrobial therapy—predominantly following diagnostic confirmation (98.52%), although some were treated based on clinical presentation and medical history (1.48%). The overall eradication rate was 81.72%. An amoxicillin-based triple therapy demonstrated the highest eradication rate (73.02%) compared to other regimens (p < 0.001). Furthermore, a longer duration of therapy was significantly associated with an increased eradication rate (p < 0.001). The prevalence of H. pylori in this cohort was relatively low compared to populations sharing similar geographic, ethnic, and socioeconomic characteristics. Eradication success was significantly influenced by the type of treatment regimen (p < 0.001), age group (p < 0.001), gender (p = 0.015), use of PPIs or H2 blockers (p < 0.001), and duration of therapy (p < 0.001). These findings underline the importance of personalized treatment approaches and optimization of therapy duration to improve eradication rates.
